Vtv Therapeutics INC

vTv Therapeutics Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

vTv Therapeutics has filed a prospectus supplement to increase the number of shares available under its existing at-the-market sales program.

vTv Therapeutics Inc. posted an updated investor presentation highlighting its lead asset, Cadisegliatin, in Phase 3 development for Type 1 Diabetes with topline data expected in 2H 2026.

vTv Therapeutics' subsidiary, vTv LLC, amended its license agreement with Newsoara Biopharma, expanding global rights for its PDE4 inhibitor HPP737 for an upfront payment of $20 million and potential milestones up to $115 million plus royalties.

vTv Therapeutics Inc. amended its by-laws, reducing the quorum requirement for stockholder meetings to 33.4%.

vTv Therapeutics reported Q3 2025 financial results, highlighted by an $80 million private placement and progress in its Phase 3 CATT1 trial for type 1 diabetes.

vTv Therapeutics Inc. reported a significant revenue increase in Q1 2026 driven by an upfront payment from Newsoara Biopharma, while research and development expenses also rose.

vTv Therapeutics Inc. reported an increased net loss for Q3 2025 but significantly strengthened its cash position through a recent private placement, removing prior going concern doubts.

vTv Therapeutics Inc. reported an increased net loss in the second quarter of 2025, driven by higher research and development expenses, as it reinitiates its pivotal Phase 3 CATT1 trial for cadisegliatin in Type 1 diabetes.

vTv Therapeutics announces its Q1 2025 financial results and the reinitiation of the CATT1 trial for cadisegliatin following the lifting of a clinical hold by the FDA.

vTv Therapeutics reported its third quarter 2024 financial results, highlighting a revenue of $1 million and a net loss of $4.783 million, while also providing an update on its clinical programs and recent corporate activities.

vTv Therapeutics reported its second quarter 2024 financial results, highlighting a revenue of $1 million and a net loss of $10.045 million, while also announcing a clinical hold on its cadisegliatin program.

vTv Therapeutics is set to resume its Phase 3 trial for cadisegliatin in Type 1 Diabetes after the FDA lifted a clinical hold, paving the way for further development of the potential adjunctive therapy.

vTv Therapeutics Inc. released its 10-K filing, detailing financial results and progress in clinical trials, particularly for its lead drug candidate, cadisegliatin, for type 1 diabetes.

Baker Bros. Advisors LP, through its associated entities and individuals, has acquired 6,000 non-qualified stock options for vTv Therapeutics Inc. (VTVT) as part of director compensation.

Daniel K. Spiegelman, a Director at VTV Therapeutics Inc., acquired stock options for 6,000 shares of Class A Common Stock.

A VTVT director acquired stock options, indicating a potential long-term commitment to the company's performance.

Fahed Al-Marzooqi, a director at vTv Therapeutics Inc., acquired stock options granting the right to buy 6,000 shares.

Anne M. Phillips, a Director at vTv Therapeutics Inc., acquired stock options for 6,000 shares.

Srinivas Akkaraju, a director of vTv Therapeutics Inc., reported significant acquisitions of common stock and warrants through affiliated funds.

vTv Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to elect directors and ratify auditor appointment.

vTv Therapeutics Inc. will hold its annual meeting of stockholders virtually on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

vTv Therapeutics is holding its annual meeting on June 11, 2024, to elect directors, approve an equity incentive plan, and ratify the appointment of its accounting firm.

Samsara BioCapital, L.P. reported a sale of 75,965 shares of VTV Therapeutics Class A Common Stock at $21.25 per share in a private transaction.

Samsara BioCapital and Samsara Opportunity Fund increased their beneficial ownership in VTV Therapeutics Inc. Class A Common Stock to 9.9% following a $15.0 million private placement.

VTV Therapeutics Inc. has entered into a securities purchase agreement for a private placement totaling $25 million, involving Samsara BioCapital funds.

Several entities affiliated with Millennium Management have reported beneficial ownership of vTv Therapeutics Inc. Class A Common Stock, collectively holding approximately 6.9% of the outstanding shares.

Millennium Management and affiliated entities have filed a Schedule 13G reporting a 5.7% beneficial ownership stake in vTv Therapeutics Inc.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has reported a 5.0% beneficial ownership stake in vTv Therapeutics Inc.

Raymond Debbane and affiliated entities, including Invus Public Equities, report a combined beneficial ownership of 9.4% in vTv Therapeutics Inc. Class A Common Stock.

Trails Edge Capital Partners, LP and affiliates have reported a 9.9% passive ownership stake in vTv Therapeutics Inc. common stock.

Investment entities linked to Raymond Debbane have reported a 9.99% beneficial ownership in vTv Therapeutics Inc., including common stock and warrants.